News
TLPH
1.035
-1.43%
-0.015
Talphera Files Prospectus To Offer Up to $150M In Securities
Benzinga · 4h ago
Talphera files $150M mixed securities shelf
TipRanks · 4h ago
Talphera GAAP EPS of -$0.05 beats by $0.01
Seeking Alpha · 5h ago
Here are the major earnings after the close Thursday
Seeking Alpha · 11h ago
Weekly Report: what happened at TLPH last week (1102-1106)?
Weekly Report · 3d ago
Weekly Report: what happened at TLPH last week (1026-1030)?
Weekly Report · 11/02 09:05
Weekly Report: what happened at TLPH last week (1019-1023)?
Weekly Report · 10/26 09:05
Weekly Report: what happened at TLPH last week (1012-1016)?
Weekly Report · 10/19 09:05
Weekly Report: what happened at TLPH last week (1005-1009)?
Weekly Report · 10/12 09:06
Weekly Report: what happened at TLPH last week (0928-1002)?
Weekly Report · 10/05 09:06
Weekly Report: what happened at TLPH last week (0921-0925)?
Weekly Report · 09/28 09:05
Talphera (TLPH) Upgraded to Buy: Here's What You Should Know
NASDAQ · 09/21 16:00
Weekly Report: what happened at TLPH last week (0914-0918)?
Weekly Report · 09/21 09:05
Weekly Report: what happened at TLPH last week (0907-0911)?
Weekly Report · 09/14 09:06
Weekly Report: what happened at TLPH last week (0831-0904)?
Weekly Report · 09/07 09:05
Weekly Report: what happened at TLPH last week (0824-0828)?
Weekly Report · 08/31 09:06
Weekly Report: what happened at TLPH last week (0817-0821)?
Weekly Report · 08/24 09:06
Talphera Earnings Call Highlights Nafamostat Momentum
TipRanks · 08/24 00:23
Weekly Report: what happened at TLPH last week (0810-0814)?
Weekly Report · 08/17 09:06
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT)
TipRanks · 08/14 13:00
More
Webull provides a variety of real-time TLPH stock news. You can receive the latest news about Talphera Inc through multiple platforms. This information may help you make smarter investment decisions.
About TLPH
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.